NewsBenzingaBiohavenの第1相データ、ENA 2026の口頭全体会で発表され、FGFR3変異尿路上皮がんおよび頭頸部扁平上皮癌の患者において深く持続的な奏効を示す Biohavenの第1相データ、ENA 2026の口頭全体会で発表され、FGFR3変異尿路上皮がんおよび頭頸部扁平上皮癌の患者において深く持続的な奏効を示す Benzinga 2026.11.19 12:37 (GMT+0) Open on Benzinga Other news Biohaven's Phase 1 Data Presented In Oral Plenary Session At ENA 2026 Shows Deep, Durable Responses In Patients With FGFR3-Altered Urothelial Cancer And Head And Neck Squamous Cell Carcinoma Clearmind Medicine Publishes Hong Kong Patent Application Covering Innovative Psychedelic Compounds Targeting Treatment Of PTSD And Other Mental Health Disorders Warner Music Gr Q4 Adj. EPS $0.55 Beats $0.36 Estimate, Sales $2.001B Beat $1.906B Estimate Biohaven Presents Clinical Data From Ongoing Phase 1 Study Of BHV-1530, Potential FGFR3-Directed ADC With Topoisomerase I Payload, At ENA 2026 Bernstein Maintains Outperform on Agilon Health, Raises Price Target to $138 Palo Alto Networks Stock Soars: Investors Cheer Strong Outlook, Applied Compute Acquisition
Biohaven's Phase 1 Data Presented In Oral Plenary Session At ENA 2026 Shows Deep, Durable Responses In Patients With FGFR3-Altered Urothelial Cancer And Head And Neck Squamous Cell Carcinoma
Clearmind Medicine Publishes Hong Kong Patent Application Covering Innovative Psychedelic Compounds Targeting Treatment Of PTSD And Other Mental Health Disorders
Biohaven Presents Clinical Data From Ongoing Phase 1 Study Of BHV-1530, Potential FGFR3-Directed ADC With Topoisomerase I Payload, At ENA 2026